Overview

• Preclinical mice studies showed the eyedrop reached the retina, a site typically accessed only by intravitreal injections.
• The cubosome-based formulation kept lutein stable for months at room temperature.
• In lab tests, the delivered compound protected retinal cells from stress linked to vision loss, with results reported in ACS Applied Materials & Interfaces (DOI: 10.1021/acsami.5c14464).
• Researchers say the RMIT-patented cubosome carrier could be adapted to transport other therapeutics to the back of the eye.
• The study did not assess disease outcomes in AMD models, and the team is seeking clinical and industry partners to advance testing toward human trials.